Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 18:12:251-258.
doi: 10.2147/BCTT.S219436. eCollection 2020.

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Avan J Armaghani  1 , Hyo Sook Han  1
Affiliations
Review

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Avan J Armaghani et al. Breast Cancer (Dove Med Press). .

Abstract

Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tailored and targeted therapies. Recently, greater understanding of the role of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in breast cancer has led to the development of PI3K inhibitors, which have proven to be effective in the treatment of HR+/HER2 negative MBC. In this review, we will discuss the role of the PI3K/AKT/mTOR pathway in breast cancer and therapies that have been developed to inhibit PI3K. We will discuss in detail the development of PI3K inhibitor alpelisib, indications for use in HR+/HER2 negative MBC, safety and tolerability and the future direction of this therapy in the treatment of breast cancer.

Keywords: PI3K; PIK3CA; alpelisib.

PubMed Disclaimer

Conflict of interest statement

Dr Hyo Sook Han reports personal fees from Lilly, research funding to institution from Arvinas, Abbvie, BMS, Daiichi, G1 therapeutics, GSK, Horizon, Maker therapeutics, Novartis, Pfizer, Prescient, Seattle Genetics, Zymeworks, grants from Department of Defense, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Therapeutic strategies have been developed to target various steps in the PI3K/AKT/mTOR pathway, thereby blocking cell proliferation, growth and survival.
See this image and copyright information in PMC

References

    1. Society AC Breast cancer facts and figures 2019–2020. September 10, 2020; Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-.... Accessed October8, 2020.
    1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925. doi: 10.1056/NEJMoa1607303 - DOI - PubMed
    1. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi: 10.1200/JCO.2017.75.6155 - DOI - PubMed
    1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi: 10.1056/NEJMoa1609709 - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). Breast cancer. Version 3.2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April1, 2020.